ArticleReports of biochemistry & molecular biology2025
Cross-Regional Transcriptome Data Reveal Transcriptional Abnormalities Associated with Lung Adenocarcinoma.
Article in Reports of biochemistry & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serglycin Across the Disease Spectrum: A Multifunctional Proteoglycan in Inflammation and Cancer.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the leading cause of cancer-related deaths worldwide, yet there has been little attention given to the correlation between the cancer transcriptome and the incidence and mortality of lung cancer across different geographic regions. Methods: To analyze this correlation, we screened the transcriptome datasets of stage I lung adenocarcinoma (LAC) patients from the Lung Cancer Explorer and examined their correlation with the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and mortality-to-incidence ratio (MIR). Results: The expression difference rates (DRs) of certain genes (SPARCL1, SRPX, PMP22, MSR1, BST1, AKAP12, MAOB, vimentin, serglycin, ILK, ESD, transgelin, NCOA1, and PLPP1) were significantly negatively correlated with the ASIR of female LAC. Additionally, the DR of KRT19 was significantly positively correlated with the ASIR of female LAC. Furthermore, the DRs of COL10A1, SMAD7, COL3A1, and AQP1 were significantly positively correlated with the ASMR and MIR of female LAC, while the DR of KRT15 was significantly negatively correlated with the ASMR and MIR of female LAC. In male LAC patients, the DR of RGS2 was significantly negatively correlated with the ASIR, while the DRs of SPARCL1, COX7A1, IL3RA, and ADH1B were significantly positively correlated with the ASMR and MIR. Additionally, the DR of AIMP2 was significantly negatively correlated with the ASMR and MIR. Conclusions: Our findings suggest that the expression levels of serglycin, ILK, ESD, and PLPD1 may play a significant role in the development of LAC. This information can be valuable for identifying potential treatment targets for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.